B-ALL is a hematologic malignancy characterized by the uncontrollable proliferation of immature B-cell lymphoblasts. A hallmark of this disease lies in genomic structural variants—specifically, fusion oncogenes formed from chromosomal rearrangements. These fusion genes act as oncogenic drivers, accelerating cancer cell growth and rendering precise molecular diagnosis essential for tailoring patient-specific treatment strategies. Currently, clinical diagnostics for B-ALL rely on a battery of assays including fluorescence in situ hybridization (FISH), immunohistochemistry, and other complex molecular tests, each targeting distinct genetic abnormalities. This fragmented approach not only demands multiple laboratory resources but also increases turnaround time and costs.

The revolutionary algorithm, named FUSILLI (FUSions In Leukemia for Long-read sequencing Investigator), leverages Oxford Nanopore Technologies’ (ONT) long-read whole-transcriptome sequencing (WTS) to directly detect fusion transcripts in B-ALL samples. Unlike traditional short-read sequencing, long-read sequencing captures extended RNA or DNA fragments in one continuous read, facilitating the identification of structural variants with high precision and reduced ambiguity. Importantly, ONT’s platform offers advantages such as lower capital investment, reduced reagent costs, and rapid data generation, making it particularly accessible for diverse clinical settings, including those with limited resources.

FUSILLI represents a critical advancement by specifically tailoring fusion detection algorithms to the unique challenges posed by long-read sequence data derived from pediatric leukemia samples. The research team employed sophisticated filtering techniques to differentiate true gene fusions from sequencing artifacts, such as chimeric reads that may mimic fusion events during nanopore sequencing. Their methodology sets a minimum threshold of two supporting fusion reads per sample to maximize diagnostic accuracy while minimizing false positives caused by technical or computational noise.

A major accomplishment of this study was establishing the minimum sequencing depth required for reliable detection of fusion oncogenes in B-ALL. The authors determined that sequencing roughly 10 million reads per sample strikes a balance between sensitivity and cost-efficiency, enabling the consistent identification of both primary leukemogenic fusions and potentially clinically relevant secondary alterations. These secondary fusions, including recurrent events like PAX5::ZCCHC7, represent an under-explored frontier in leukemia biology, and detecting them could yield novel insights into disease heterogeneity and treatment responses.

Comparative analyses with existing fusion detection algorithms demonstrated that FUSILLI surpasses publicly available tools in sensitivity without compromising specificity. Notably, by focusing exclusively on clinically relevant fusion transcripts associated with B-ALL, the algorithm operates within a streamlined search space, thereby reducing computational overhead and accelerating turnaround times in clinical workflows. This precision-targeted approach aligns seamlessly with real-world diagnostic needs where rapid, accurate results are paramount.

The implications of this technology extend far beyond mere detection. By consolidating multiple diagnostic assays into a single sequencing platform, FUSILLI could significantly reduce the complexities and costs associated with current standard-of-care testing. Moreover, the rapid turnaround achievable with ONT sequencing and FUSILLI analysis holds promise for clinical scenarios requiring urgent molecular information to guide therapy intensification or de-escalation.

Senior investigator Dr. Jeremy R. Wang, PhD, highlights that while long-read sequencing has existed for over a decade, its maturation now enables translational applications that were previously unattainable. According to Dr. Wang, “Long-read sequencing, and nanopore sequencing specifically, herald a new era in genomic diagnostics by overcoming intrinsic limitations of short-read technologies and democratizing access through cost reductions and simplified workflows.” These attributes are particularly impactful in pediatric oncology, where timely risk stratification governs critical treatment decisions that affect survival and quality of life.

By embracing FUSILLI, clinical laboratories could usher in a paradigm shift, transforming the landscape of pediatric B-ALL diagnostics. The ability to perform sensitive fusion detection with a single low-coverage sequencing assay promises to improve diagnostic accuracy, accelerate treatment initiation, and ultimately enhance patient outcomes. Additionally, uncovering novel genomic alterations unobtainable by conventional methods may pave the way for personalized therapeutic interventions and refined prognostic models in the near future.

This study also underscores the value of interdisciplinary collaboration, integrating geneticists, pathologists, computational biologists, and clinicians to tackle the intricate challenges of leukemia genomics. As the research community continues to validate and refine FUSILLI, further enhancements in algorithmic performance and sequencing technology are expected to broaden applicability across diverse hematologic malignancies.

In the broader context of oncology, advances like FUSILLI exemplify how state-of-the-art genomics can catalyze precision medicine, allowing treatments to be customized based on profound molecular understanding. The reduction in assay complexity, cost, and turnaround time holds significant promise for equitable access to molecular diagnostics, especially in underserved healthcare systems worldwide.

Ultimately, the success of this novel approach exemplifies how innovation in sequencing technology and bioinformatics can converge to address pressing clinical needs in pediatric cancer. With ongoing integration into diagnostic workflows, FUSILLI stands poised to enhance the standard of care for children with B-ALL, contributing to improved survival rates and reduced treatment-associated toxicities.

Subject of Research: Cells
Article Title: Long-Read Whole-Transcriptome Sequencing and Selective Gene Panel Profiling Enable Sensitive Detection of Fusion Oncogenes in Pediatric B-Cell Acute Lymphoblastic Leukemia
News Publication Date: May 14, 2026
Web References: https://doi.org/10.1016/j.jmoldx.2026.01.007
References: Lin et al., The Journal of Molecular Diagnostics, 2026
Image Credits: The Journal of Molecular Diagnostics / Lin et al.
Keywords: B-cell acute lymphoblastic leukemia, pediatric cancer, gene fusions, fusion oncogenes, long-read sequencing, Oxford Nanopore Technologies, FUSILLI, genomic subtyping, molecular diagnostics, nanopore sequencing, structural variants, precision medicine

Pancreatic cancer is notorious for its silent progression during early development, often evading symptomatic detection until it reaches advanced, less treatable phases. This stealth, coupled with limited early diagnostic tools, contributes to the distressingly low five-year survival rate of approximately 3% in advanced cases. The urgency to innovate affordable, sensitive screening mechanisms has driven researchers like Professor Débora Gonçalves at the São Carlos Institute of Physics, University of São Paulo, to develop this sensor with a mission to broaden early detection accessibility.

The scientific team detailed their revolutionary approach in a recent publication in ACS Omega, elucidating how their sensor selectively identifies the CA19-9 protein—a glycoprotein commonly used clinically to monitor pancreatic cancer but traditionally detectable only through intricate, time-intensive laboratory assays. By simplifying this detection into a straightforward electrochemical process, the biosensor ushers in an era of expedited diagnostics potentially suitable for widespread clinical use.

The sensor’s operational principle is elegantly biomimetic and electrochemical in nature. Its electrode surface is functionalized with antibodies specifically engineered to bind exclusively to the CA19-9 glycoprotein. Upon introduction of a blood sample, the immobilized antibodies capture any present CA19-9 molecules, creating a biochemical “lock and key” interaction. This biomolecular binding perturbs the electrical charge distribution on the electrode surface, which the device then transduces into a capacitance signal detectable with precise instrumentation.

Capacitance, referring to the ability of a system to store electrical charge, varies measurably in correlation with the concentration of CA19-9 captured. The biosensor’s electronic interface translates this physical shift into quantitative data, enabling it to assess the glycoprotein’s concentration in roughly ten minutes. This rapid turnaround compares favorably with conventional assays such as enzyme-linked immunosorbent assays (ELISA), which are laborious and typically require specialized lab environments and personnel.

In clinical validation involving twenty-four blood samples across various disease stages along with control groups, the biosensor demonstrated concordant diagnostic results comparable to traditional laboratory tests. This achievement underscores the device’s potential to accurately identify pancreatic cancer biomarkers reliably, setting the stage for expanded trials and inclusion of diverse biological samples like saliva and urine, thereby broadening its practical applicability.

Going beyond mere detection, the Brazilian researchers are exploring multifaceted sensor architectures that employ differing detection principles to complement this capacitance measurement. By fusing the output from multiple biosensors, they anticipate enhancing diagnostic reliability and approximating the sensitivity and specificity standards of ELISA without its cost and infrastructural demands. This integrative approach heralds a new paradigm in point-of-care oncology diagnostics.

In parallel, the team is harnessing the power of machine learning algorithms to develop a sophisticated analytical platform termed the “bioelectronic tongue.” This system is designed to integrate, interpret, and refine biosensor data from various biological matrices such as blood, urine, and saliva. By leveraging computational pattern recognition and predictive modeling, the bioelectronic tongue aims to elevate diagnostic precision and correct potential measurement artifacts in real-time.

This fusion of cutting-edge biosensor technology, electrochemical engineering, and artificial intelligence embodies a holistic strategy addressing the multifaceted challenges of early pancreatic cancer detection. The implications for patient prognosis, treatment efficacy, and healthcare resource optimization could be profound if these devices reach clinical deployment and screening program integration.

The sensor’s underlying fabrication relies on supramolecular chemistry involving polymers such as PDDA (poly(diallyldimethylammonium chloride)) and PEDOT:PSS (poly(3,4-ethylenedioxythiophene) polystyrene sulfonate), which construct a functional interface conducive to antibody immobilization and stable electrical performance. This tailored material matrix ensures biocompatibility and enhances signal transduction fidelity, critical for discerning minute biological interactions within complex bodily fluids.

Moreover, the electrochemical measurement modality employed bypasses the extensive preparatory steps and prolonged incubation periods characteristic of standard immunoassays, delivering a rapid diagnostic workflow compatible with clinical exigencies. The compactness and affordability of the technology suggest its suitability for decentralized testing settings, potentially empowering primary healthcare providers and facilitating mass screening initiatives in underserved regions.

As this pioneering research advances, the anticipation is that such biosensors could fundamentally shift the detection timeline for pancreatic cancer, enabling clinicians to initiate therapeutic interventions earlier, improving survival outcomes dramatically. Furthermore, the adaptability of the sensor platform may extend its utility to other biomarkers and diseases, signifying a broader impact on precision medicine.

With ongoing validation, expansion of sample types, and integration with machine learning analytics, the biosensor represents a compelling leap toward democratizing cancer diagnosis. This fusion of bioengineering and data science underscores the dynamic intersection defining next-generation biomedical innovations aimed at saving lives through empowerment, accessibility, and technological excellence.

Subject of Research: Electrochemical biosensor for early pancreatic cancer detection through CA19-9 biomarker analysis.

Article Title: Supramolecular PDDA/PEDOT:PSS Biosensor for Early Pancreatic Cancer Detection via CA19-9: Clinical Validation on Human Blood Samples

News Publication Date: 22-Jan-2026

Web References:
https://pubs.acs.org/doi/10.1021/acsomega.5c11381
http://www.fapesp.br/en

References:
Gonçalves, D., Soares, G. O. N., et al. “Supramolecular PDDA/PEDOT:PSS Biosensor for Early Pancreatic Cancer Detection via CA19-9: Clinical Validation on Human Blood Samples,” ACS Omega, 2026. DOI: 10.1021/acsomega.5c11381

Image Credits: Gabriella Soares

Keywords

Pancreatic cancer, electrochemical biosensor, CA19-9, early detection, capacitance measurement, PDDA, PEDOT:PSS, antibody immobilization, biomarker, ELISA alternative, bioelectronic tongue, machine learning, biomedical diagnostics